Abstract
The Advocate-General of the European Court of Justice (ECJ) has delivered an important opinion that, if adopted by the judges of the court, would mean an extension in the availability of Supplementary Protection Certificates (SPCs) throughout the European Union (EU). In Case C-431/04 Massachusetts Institute of Technology (unreported opinion of 24th November, 2005), 1 the Advocate-General proposed a broad interpretation of the definition of the products for which an SPC could be obtained, arguing that a `combination medicinal product' comprising an active ingredient and an excipient could be considered as a product attracting SPC protection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
